TY - JOUR
T1 - Gut–liver axis, cirrhosis and portal hypertension
T2 - the chicken and the egg
AU - Arab, Juan P.
AU - Martin-Mateos, Rosa M.
AU - Shah, Vijay H.
N1 - Funding Information:
This work was supported by grant(s) NIH DK59615 and AA021171 (VHS), the Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567). Arab JP was funded by an award from AASLD Foundation (AASLD/LIFER Clinical and Translational Research Fellowship in Liver Diseases). The authors also thanks Mrs. Terri Johnson for her secretarial assistance. Juan P. Arab, Rosa M. Martin-Mateos and Vijay H. Shah have nothing to disclose.
Funding Information:
Acknowledgements This work was supported by grant(s) NIH DK59615 and AA021171 (VHS), the Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567). Arab JP was funded by an award from AASLD Foundation (AASLD/ LIFER Clinical and Translational Research Fellowship in Liver Diseases). The authors also thanks Mrs. Terri Johnson for her secretarial assistance.
Publisher Copyright:
© 2017, Asian Pacific Association for the Study of the Liver.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The term gut–liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. The intestine has a highly specialized epithelial membrane which regulates transport across the mucosa. Due to dysbiosis, impairment of the intestinal barrier and altered immunity status, bacterial products can reach the liver through the portal vein, where they are recognized by specific receptors, activate the immune system and lead to a proinflammatory response. Gut microbiota and bacterial translocation play an important role in the pathogenesis of chronic liver diseases, including alcoholic and non-alcoholic fatty liver disease, cirrhosis, and its complications, such as portal hypertension, spontaneous bacterial peritonitis and hepatic encephalopaty. The gut microbiota also plays a critical role as a modulator of bile acid metabolism which can also influence intestinal permeability and portal hypertension through the farnesoid-X receptor. On the other hand, cirrhosis and portal hypertension affect the microbiota and increase translocation, leading to a “chicken and egg” situation, where translocation increases portal pressure, and vice versa. A myriad of therapies targeting gut microbiota have been evaluated specifically in patients with chronic liver disease. Further studies targeting intestinal microbiota and its possible hemodynamic and metabolic effects are needed. This review summarizes the current knowledge about the role of gut microbiota in the pathogenesis of chronic liver diseases and portal hypertension.
AB - The term gut–liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. The intestine has a highly specialized epithelial membrane which regulates transport across the mucosa. Due to dysbiosis, impairment of the intestinal barrier and altered immunity status, bacterial products can reach the liver through the portal vein, where they are recognized by specific receptors, activate the immune system and lead to a proinflammatory response. Gut microbiota and bacterial translocation play an important role in the pathogenesis of chronic liver diseases, including alcoholic and non-alcoholic fatty liver disease, cirrhosis, and its complications, such as portal hypertension, spontaneous bacterial peritonitis and hepatic encephalopaty. The gut microbiota also plays a critical role as a modulator of bile acid metabolism which can also influence intestinal permeability and portal hypertension through the farnesoid-X receptor. On the other hand, cirrhosis and portal hypertension affect the microbiota and increase translocation, leading to a “chicken and egg” situation, where translocation increases portal pressure, and vice versa. A myriad of therapies targeting gut microbiota have been evaluated specifically in patients with chronic liver disease. Further studies targeting intestinal microbiota and its possible hemodynamic and metabolic effects are needed. This review summarizes the current knowledge about the role of gut microbiota in the pathogenesis of chronic liver diseases and portal hypertension.
KW - Bile acids
KW - Cirrhosis
KW - Endotoxemia
KW - Gut–liver axis
KW - LPS
KW - Microbiota
KW - Portal hypertension
KW - Translocation
UR - http://www.scopus.com/inward/record.url?scp=85019722377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019722377&partnerID=8YFLogxK
U2 - 10.1007/s12072-017-9798-x
DO - 10.1007/s12072-017-9798-x
M3 - Article
C2 - 28550391
AN - SCOPUS:85019722377
SN - 1936-0533
VL - 12
SP - 24
EP - 33
JO - Hepatology International
JF - Hepatology International
ER -